Axsome Therapeutics, Inc. (NASDAQ:AXSM) Shares Bought by Pallas Capital Advisors LLC

Pallas Capital Advisors LLC raised its position in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 33.5% during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 35,280 shares of the company's stock after acquiring an additional 8,845 shares during the period. Pallas Capital Advisors LLC owned approximately 0.07% of Axsome Therapeutics worth $4,115,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also bought and sold shares of the company. NBC Securities Inc. purchased a new position in shares of Axsome Therapeutics during the 1st quarter worth about $31,000. Raiffeisen Bank International AG bought a new stake in Axsome Therapeutics in the fourth quarter worth about $51,000. Assetmark Inc. purchased a new position in shares of Axsome Therapeutics during the fourth quarter valued at approximately $52,000. Aquatic Capital Management LLC bought a new position in shares of Axsome Therapeutics during the fourth quarter valued at approximately $76,000. Finally, GF Fund Management CO. LTD. purchased a new stake in shares of Axsome Therapeutics in the fourth quarter worth approximately $86,000. Institutional investors own 81.49% of the company's stock.

Insider Transactions at Axsome Therapeutics

In other Axsome Therapeutics news, Director Mark Coleman sold 3,750 shares of the business's stock in a transaction that occurred on Tuesday, May 27th. The shares were sold at an average price of $105.47, for a total transaction of $395,512.50. Following the sale, the director now owns 50,387 shares of the company's stock, valued at approximately $5,314,316.89. The trade was a 6.93% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, COO Mark L. Jacobson sold 20,673 shares of the company's stock in a transaction that occurred on Tuesday, May 27th. The shares were sold at an average price of $104.66, for a total transaction of $2,163,636.18. Following the transaction, the chief operating officer now owns 5,783 shares in the company, valued at $605,248.78. The trade was a 78.14% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 72,423 shares of company stock valued at $7,711,619 in the last 90 days. Insiders own 22.30% of the company's stock.

Axsome Therapeutics Stock Down 1.7%

NASDAQ AXSM traded down $1.83 during midday trading on Thursday, hitting $106.25. 447,175 shares of the company traded hands, compared to its average volume of 677,955. The company has a market cap of $5.23 billion, a PE ratio of -17.74 and a beta of 0.47. The company has a debt-to-equity ratio of 3.22, a current ratio of 2.11 and a quick ratio of 2.04. Axsome Therapeutics, Inc. has a 52 week low of $70.11 and a 52 week high of $139.13. The company's 50-day simple moving average is $106.16 and its 200-day simple moving average is $106.84.

Analyst Ratings Changes

A number of equities analysts recently issued reports on AXSM shares. Truist Financial boosted their price objective on Axsome Therapeutics from $190.00 to $200.00 and gave the company a "buy" rating in a report on Wednesday, February 19th. Mizuho upped their price target on shares of Axsome Therapeutics from $212.00 to $216.00 and gave the stock an "outperform" rating in a report on Thursday, March 27th. HC Wainwright reaffirmed a "buy" rating and issued a $180.00 price target on shares of Axsome Therapeutics in a research note on Tuesday. Morgan Stanley boosted their price objective on shares of Axsome Therapeutics from $125.00 to $190.00 and gave the company an "overweight" rating in a research report on Thursday, February 27th. Finally, Wells Fargo & Company reaffirmed an "overweight" rating and set a $165.00 target price (up from $160.00) on shares of Axsome Therapeutics in a research report on Tuesday, May 6th. One equities research analyst has rated the stock with a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus target price of $172.33.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.